GlaxoSmithKline’s bid for Human Genome Sciences cleared, but rejected by HGS Board
The Hart-Scott-Rodino waiting period for GlaxoSmithKline’s (GSK) tender offer for Human Genome Sciences (HGS) has expired. Human Genome Sciences is a Rockville, MD-based biopharmaceutical corporation. Under the terms of the offer, GSK would buy all outstanding shares of HGS for $13/share in cash.
However, the HGS Board of Directors has rejected the offer as inadequate and urged shareholders to reject the offer as well. According to the HGS press release in response to the HSR termination announcement, GSK’s tender offer was unsolicited and “seeks to circumvent, disrupt and prematurely end [HGS’s] strategic review process.
Full content: MarketWatch
Related content: New Horizontal Merger Guidelines Indicate Greater Scrutiny of High Tech and Pharmaceutical Transactions (Janet McDavid & Eric Stock, Hogan Lovells)
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI